Aino Health (AINO) Q4 2025 earnings summary

Executive summary

• Expanded license base to 116,000, driven by new customer acquisitions and increased adoption within existing customers.

• Strengthened financing position with SEK 7.7 million package to accelerate international growth.

• Advanced product development, research, and AI initiatives to enhance platform capabilities and customer value.

• Signed new contracts with major occupational health and industrial automation providers, expanding market reach.

Financial highlights

• Net sales for Q4 2025 were KSEK 5,426, down from KSEK 6,000 in Q4 2024; full-year 2025 net sales were KSEK 26,112, up from KSEK 23,941 in 2024.

• Q4 2025 loss after financial items was KSEK -3,678, compared to KSEK -3,451 in Q4 2024; full-year 2025 loss after financial items was KSEK -6,111, improved from KSEK -9,915 in 2024.

• Operating profit (EBIT) for Q4 2025 was KSEK -3,362, compared to KSEK -3,225 in Q4 2024.

• Cash flow for Q4 2025 was KSEK 5,136, a significant improvement from KSEK -787 in Q4 2024.

• Available cash at year-end 2025 was KSEK 5,806, with liquidity strengthened by new loans.

Outlook and guidance

• Priorities for 2026 include accelerating deployments, expanding within existing customers, focused international growth, and continued investment in product and security.

• Demand for proactive work ability management is expected to remain strong, driven by structural labor market factors.